Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactate and IPC for Endothelial I/R Injury
NCT06825143Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lactate in ischemia-reperfusion injury (IRI) (2 arms). Primary endpoint: Mean peak forearm blood flow response to reactive hyperemia at 3 hours. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
lactate
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT06825143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825143.